Tags

Type your tag names separated by a space and hit enter

Acute migraine therapy: recent evidence from randomized comparative trials.
Curr Opin Neurol. 2008 Jun; 21(3):331-7.CO

Abstract

(1) A wide array of data regarding acute migraine treatment are available, but few trials strictly adhere to International Headache Society guidelines for patient inclusion criteria.(2) Triptans appear to have similar efficacy profiles, but among newer triptans, almotriptan offers improved tolerability over sumatriptan.(3) Combination indomethacin/caffeine/prochlorperazine most likely has similar therapeutic efficacy to triptan therapy, with further research needed to complete understanding of any potential differences between these treatments.(4) Multi-targeted combination therapy with a triptan plus a non-steroidal anti-inflammatory (NSAID), such as sumatriptan/naproxen sodium, is more effective in acute migraine treatment than monotherapy with either agent alone.(5) It is unclear whether triptans offer clinically relevant benefits over aspirin or NSAIDs in migraine patients. Thus NSAIDs, particularly effervescent aspirin, should be considered the first-line treatment of migraine attacks.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Mett A
Wolters Kluwer Health | Adis, Auckland, New Zealand.
Tfelt-Hansen P
No affiliation info available

MeSH

Acute DiseaseAnalgesicsAnti-Inflammatory Agents, Non-SteroidalAntiemeticsCaffeineCentral Nervous System StimulantsDrug Therapy, CombinationErgotamineHumansIndomethacinMigraine DisordersProchlorperazineRandomized Controlled Trials as TopicSerotonin Receptor AgonistsTreatment OutcomeTryptaminesVasoconstrictor Agents

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

18451718

Citation

Mett, Anna, and Peer Tfelt-Hansen. "Acute Migraine Therapy: Recent Evidence From Randomized Comparative Trials." Current Opinion in Neurology, vol. 21, no. 3, 2008, pp. 331-7.
Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol. 2008;21(3):331-7.
Mett, A., & Tfelt-Hansen, P. (2008). Acute migraine therapy: recent evidence from randomized comparative trials. Current Opinion in Neurology, 21(3), 331-7. https://doi.org/10.1097/WCO.0b013e3282fee843
Mett A, Tfelt-Hansen P. Acute Migraine Therapy: Recent Evidence From Randomized Comparative Trials. Curr Opin Neurol. 2008;21(3):331-7. PubMed PMID: 18451718.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute migraine therapy: recent evidence from randomized comparative trials. AU - Mett,Anna, AU - Tfelt-Hansen,Peer, PY - 2008/5/3/pubmed PY - 2008/7/26/medline PY - 2008/5/3/entrez SP - 331 EP - 7 JF - Current opinion in neurology JO - Curr Opin Neurol VL - 21 IS - 3 N2 - (1) A wide array of data regarding acute migraine treatment are available, but few trials strictly adhere to International Headache Society guidelines for patient inclusion criteria.(2) Triptans appear to have similar efficacy profiles, but among newer triptans, almotriptan offers improved tolerability over sumatriptan.(3) Combination indomethacin/caffeine/prochlorperazine most likely has similar therapeutic efficacy to triptan therapy, with further research needed to complete understanding of any potential differences between these treatments.(4) Multi-targeted combination therapy with a triptan plus a non-steroidal anti-inflammatory (NSAID), such as sumatriptan/naproxen sodium, is more effective in acute migraine treatment than monotherapy with either agent alone.(5) It is unclear whether triptans offer clinically relevant benefits over aspirin or NSAIDs in migraine patients. Thus NSAIDs, particularly effervescent aspirin, should be considered the first-line treatment of migraine attacks. SN - 1350-7540 UR - https://www.unboundmedicine.com/medline/citation/18451718/Acute_migraine_therapy:_recent_evidence_from_randomized_comparative_trials_ DB - PRIME DP - Unbound Medicine ER -